Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.
In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.
The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.
- Headquartered in Madison, Wisconsin
- Specializes in cancer screening and diagnostic tests
- Flagship product: Cologuard, a noninvasive colorectal cancer screening test
- Precision oncology products: Oncotype DX and OncoExTra
- Active development of liquid biopsy tests
- Exclusive intellectual property rights protecting screening technology
For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.
Exact Sciences Corp. (Nasdaq: EXAS) anticipates reporting a 2020 fourth-quarter revenue of $464.5 million to $467.5 million. Expected Screening revenue is projected between $249 million and $250 million, marking a 9% increase year-over-year. The company anticipates Precision Oncology revenue of $117 million to $118 million and COVID-19 testing revenue between $98.5 million and $99.5 million. While these estimates are promising, they are preliminary and subject to change pending completion of the financial statements.
Exact Sciences Corp. (Nasdaq: EXAS) has finalized its acquisition of Thrive Earlier Detection Corp., a significant move towards establishing blood-based multi-cancer screening as a standard practice. CEO Kevin Conroy emphasized the strategic importance of this acquisition in revolutionizing cancer diagnostics and improving early detection and treatment options for patients. The company is committed to advancing its product pipeline, building on successes like Cologuard and Oncotype DX. This acquisition is aimed at addressing some of the most lethal cancers and enhancing patient care.
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. EST. Investors can join the discussion via webcast, accessible through the investor relations section of Exact Sciences' website.
This leading cancer diagnostics company aims to advance patient care and tackle deadly cancers through innovative solutions. For more details, visit exactsciences.com.
Exact Sciences Corp. (NASDAQ: EXAS) presented new data at the 2020 San Antonio Breast Cancer Symposium (SABCS), emphasizing the Oncotype DX Breast Recurrence Score test's role in personalizing early breast cancer treatment. The ADAPT study revealed that patients with clinically high-risk node-negative or node-positive disease can forgo chemotherapy based on favorable Recurrence Score results, achieving a 5-year distant disease-free survival rate of 96%. A new RSClin tool will provide individualized estimates for chemotherapy benefits, enhancing treatment discussions. The meta-analysis integrates findings from over 10,000 patients.
Exact Sciences Corp. (NASDAQ: EXAS) announced significant findings from the RxPONDER trial, presented at the 2020 San Antonio Breast Cancer Symposium, indicating that the Oncotype DX test can help avoid unnecessary chemotherapy for the majority of postmenopausal women with node-positive early-stage breast cancer. The study involved over 5,000 participants, revealing that two-thirds of postmenopausal women showed no chemotherapy benefit, while premenopausal women had a minor benefit. This research aims to refine treatment decisions and could impact tens of thousands of women globally.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in the Evercore ISI HealthCONx Conference on December 2, 2020, at 1:00 p.m. EST.
Investors can access the webcast through the investor relations section of the company's website.
Exact Sciences focuses on cancer screening and diagnostics, investing in its product pipeline to address various cancers and improve patient care.
For more details, visit exactsciences.com.
Exact Sciences Corp. (Nasdaq: EXAS) announced participation in two investor conferences in November 2020. These include a fireside chat at the Stifel Virtual Healthcare Conference on November 16 at 9:20 a.m. EST, and a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18 at 2:55 p.m. EST. Investors can access the webcasts via the company's website. The company specializes in cancer screening and diagnostic tests, including Cologuard and Oncotype DX, and is focused on expanding its product pipeline.
The United States Preventive Services Task Force (USPSTF) has drafted updated guidelines recommending colorectal cancer screening starting at age 45. Exact Sciences' Cologuard® is specifically included as a screening method for average-risk adults aged 45 to 75. Cologuard has demonstrated a 92% detection rate for colorectal cancers in a study involving nearly 10,000 patients. The guidelines aim to increase screening rates among 44 million unscreened Americans, highlighting a growing incidence of colorectal cancer in individuals under 50. A final recommendation is expected in 2021.
Exact Sciences Corporation (Nasdaq: EXAS) announced a registered direct offering of 8,605,483 shares at $101.00 per share, generating approximately $869.2 million in gross proceeds. The company plans to utilize the net proceeds of about $866.0 million for general corporate purposes, including debt repayment and the acquisition of Thrive Earlier Detection Corp.. The offering will close on or about October 29, 2020.
Exact Sciences Corp. (Nasdaq: EXAS) reported third-quarter revenue of $408.4 million for the period ending September 30, 2020, up from $218.8 million in 2019. Despite a 2% decrease in screening revenue at $214.6 million, they achieved $102.2 million from COVID-19 testing. The company faced a net loss of $219.9 million or $1.46 per share, a significant increase from the previous year. Gross margin was 72%, while adjusted EBITDA was $94.5 million. The company retained $1.3 billion in cash and equivalents, indicating robust liquidity.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
What is Exact Sciences Corp's main business?
What is Cologuard?
Where is Exact Sciences Corp headquartered?
What are Oncotype DX and OncoExTra?
Is Exact Sciences developing any new tests?
What is the significance of Exact Sciences' intellectual property?
Are Exact Sciences' products used internationally?
How does Cologuard work?
What is the purpose of Oncotype DX tests?
Where can more information about Cologuard be found?
